Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad's Q4 Revenues Rise 12 Percent

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said fourth-quarter revenues increased 12 percent as R&D spending rose 20 percent and profit increased 24 percent.
Total receipts for the three months ended Dec. 31, 2006, increased to $343 million from $307 million year over year.
Revenue from the company’s Life Science division rose 13 percent to $159 million, while receipts from the Clinical Diagnostics segment increased 11 percent to $180 million.
Bio-Rad said Life Science sales were “boosted by a number of factors including significant growth in protein expression analysis, process chromatography, and amplification reagents,” and by the acquisition of Ciphergen Biosystems’ tools business last year.
Clinical Diagnostics sales were up over the entire segment, but “most notably” from blood virus products and in quality-control products.
R&D spending increased to $37.4 million from $31.1 million year over year.
The company said third-quarter profit increased to $16.6 million from $13.5 million in the year-ago period.
Bio-Rad said it had around $488 million in cash, cash equivalents, and short-term investments as of Dec. 31.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.